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Abstract Serotonin is involved in several central nervous
system functions including pain threshold, mood regulation
and drug reward. Overuse of acute medications is com-
monly identified as a causative factor for medication
overuse headache (MOH). Apparently, MOH shares with
other kinds of drug addiction some common neurobio-
logical pathways. The objective of this study is to assess
the role of serotonin metabolism genes in the genetic lia-
bility to MOH. We performed a genetic association study
using polymorphisms of five serotonin metabolism-related
genes: serotonin transporter (5HTT), serotonin receptor 1A
(5-HT1A), serotonin receptor 1B (5-HT1B), serotonin
receptor 2A (5-HT2A) and serotonin receptor 6 (5HT6)
genes. We compared 138 patients with MOH with a control
sample of 117 individuals without headache and without
drug overuse, and with 101 patients with migraine without
aura but without drug overuse (MO). The genotypic and
allelic distributions of all polymorphisms investigated did
not differ among the three groups. In conclusion, our study
does not provide evidence that the 5HTT, 5-HT1A, 5HT1B,
5HT2A and 5HT6 gene polymorphisms play a role in the
genetic predisposition to MOH.
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Introduction
Chronic headache (CH), a group of headaches occurring
daily or almost daily, is a major clinical concern and a
common health risk. Overuse of acute medications, being
present in more than 80% of CH patients seen in tertiary
headache centres, is commonly identified as the most
important risk factors for CH and a causative factor for
medication overuse headache (MOH) [1].
Apparently, MOH shares with other kinds of drug
addiction some common neurobiological pathways,
including those that modulate reward, novelty seeking,
behavioural control and response to stress [2]. Liability to
drug dependence has been traced to polymorphisms in
genes regulating monoaminergic transmission [3]. In par-
ticular, several serotonin metabolism-related polymor-
phisms have been associated with addiction, psychiatric
disorders and migraine headache.
Few studies have focused on the genetics of CHs. Russell
et al. [4] found that first-degree relatives of probands with
chronic tension-type headache (CTTH) had a 2.1- to 3.9-fold
significantly increased risk of CTTH with respect to the
general population. We found that CH sufferers had signifi-
cantly higher positive family history for CH compared to
episodic headache sufferers. In particular, patients with CH
associated with drug overuse had more frequently family
history of drug overuse and substance abuse [5]. The signif-
icantly increased familial risk for CH, drug overuse and
substance abuse suggests that genetic factors are involved in
the process of headache chronification.
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Homozygosis for the short allele of the 5-HTTLPR (S/S
genotype), a polymorphism in the serotonin transporter
gene regulatory region, has been found to be associated
with an increased frequency of attacks in migraine patients
compared with those with l/S or l/l genotype [6]. Park et al.
[7] studied patients with CTTH with and without analgesic
overuse, demonstrating an excess frequency of the
5-HTTLPR short allele (S/S genotype) in the analgesic
overuse group. We performed a genetic association study
of serotonin metabolism-related genes in three population
groups: one affected with MOH, one with episodic
migraine without aura and without drug abuse (MO) and
one control population without headache and without drug
abuse.
We analysed polymorphisms in five serotonin metabo-
lism-related genes: the serotonin transporter (5HTT),
serotonin receptor 1A (5-HT1A), serotonin receptor 1B
(5-HT1B), serotonin receptor 2A (5-HT2A) and serotonin
receptor 6 (5HT6) genes. The 5HTT gene codes for a
protein responsible for the reuptake of serotonin from the
extracellular space and has an important role in determin-
ing the magnitude and duration of serotonin activity on its
pre- and post-synaptic receptors. The 5-HT1A, 5HT1B,
5HT2A and 5HT6 genes code for different serotonin
receptors.
Patient and methods
Description of analysed populations
A total of 138 unrelated patients affected with MOH aged
22–81 were compared with a control population of 117
unrelated individuals without headache and without drug
overuse, and to a population of 101 patients with episodic
migraine without aura without drug overuse (MO). All
patients were referred to the Neurological Department of
the University of Bologna and to the Headache Centre of
the University of Modena and Reggio-Emilia, two Italian
tertiary Headache Centres. To reduce stratification bias,
the populations studied came from the same region in
North-Eastern Italy, Emilia-Romagna, and all were of
Caucasian origin. The control population was composed
of healthy laboratory staff and neurological patients
without migraine. All controls and MO individual had to
be over age 40, in order to reduce ascertainment bias
related to age of onset of migraine headache. The insti-
tutional review board of the Department of Neurological
Sciences of the University of Bologna Medical School
approved the project and each patient gave informed
consent to the study.
All patients and normal subjects were diagnosed by
headache expert physician after direct interview according
to the revised diagnostic criteria of the International
Headache Society classification (ICHD-II) [8]. At the time
of the visit a headache specialist performed a semi-struc-
tured history-taking interview and a neurological exami-
nation. Patients were asked about headache characteristics
at onset and at the time of the inclusion in the study.
Headache frequency and drug overuse were evaluated by
means of headache diaries filled in for at least 3 months
previous to inclusion. All patients and controls were
investigated about family history for headache and for
substance abuse. Substance use disorders and comorbidity
for mood and anxiety disorders were diagnosed by mean of
semi-structured interviews by trained doctors and reported
according to Axis I of the DSM-IV criteria.
Genetic analysis
We studied the following DNA polymorphisms: a variable
number of tandem repeats (VNTR) of 17-base-pair (bp)
repeats located in the second intron of 5HTT localised on
chromosome 17q12 (STin 2 polymorphism: STin 2.8, STin
2.9, STin 2.10, STin 2.11, STin 2.12) [9]; a transition
A ? G at nucleotide 82 of 5-HT1A located on chromo-
some 5q11.2-q13, which leads to an amino acid exchange
(Ile ? Val) in position 28 of the receptor protein [10]; a
T ? C transition in position 102 in exon 1 of 5-HT2A that
does not alter the amino acid composition (chromosome
13q14-21) [11]; a silent G ? C substitution at position 861
in the coding sequence, and a T ? G transition at position
-261of 5-HT1B (chromosome 6q13-q15) [12], and a silent
C ? T transition in position 267 of the coding region of
the 5HT6 localised in 1p35-36 [13].
Molecular techniques for DNA extraction and amplifi-
cation were those previously reported [14]. Due to tech-
nical difficulties (DNA exhaustion, PCR failure), the
number of individuals examined in the different samples
varied (see tables).
Statistical analysis
Chi-square analysis was used to test for deviations of
genotype frequencies from Hardy–Weinberg expectations
for both biallelic systems and STin 2 polymorphism for
which only three alleles have been observed in our sample
(STin 2.8, STin 2.9 and STin 2.12). Genotypic and allelic
frequencies among the different groups were compared
using the log-linear analysis for categorical data in two-
dimensional tables or Fisher’s exact test. The test of non-
random association of alleles at different loci (linkage
disequilibrium estimate) was performed by Arlequin Soft-
ware, Ver 3.0. Multivariate logistic regression was used to
test for interaction between polymorphisms. The level of
significance was chosen as P \ 0.05. When necessary,
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P values were subject to Bonferroni’s correction for mul-
tiple comparisons.
Results
Clinical features of MOH patients are reported in Table 1.
All the polymorphisms analysed were in Hardy–
Weinberg equilibrium except for the STin 2 polymorphism
in the MOH group (v2 = 10.03, P = 0.018). The 5HT1B
(G861C) was in linkage disequilibrium with the 5-HT1B
(C-261T) polymorphism (v2 = 19.70, P = 0.00057).
The genotypic and allelic distributions of SNPs at the
5HT1B, 5HT2A and STin 2 in 5HTT did not differ among
the three groups at the exact test of population differenti-
ation as shown in Tables 2, 3 and 4.
Concerning the 5HT1A (A82G) polymorphism we found
an indication of a genetic difference in the MOH compared
to the MO group both for genotypic and for allelic distri-
bution (P = 0.039 and P = 0.049, respectively) mainly as
a result of an under-representation of allele G in the MOH
group (Table 5). However, the results were not significant
after the Bonferroni’s correction.
For the (C267T) polymorphism in the 5HT6 receptor
gene, we found a significant allelic difference in MOH
compared with control group (P = 0.033) mainly because
of an overrepresentation of allele C in the MOH group, but
we found no differences between MO and MOH (Table 6).
In this case too, the P value became non-significant after
Bonferroni’s correction. A multivariate analysis did not
show interactions between the analysed polymorphisms.
Discussion
In this genetic association study, we analysed polymor-
phisms of five genes involved in the serotonergic pathways
in patients with CH and drug overuse compared with a
control population of individuals without headache and
without drug overuse, and to a sample of patients with
migraine headache without overuse. As in our previous
study [15], these multiple comparisons were meant to
search for genetic traits specifically associated with drug
overuse in headache patients and to separate these from
possibly different liabilities to headache pain.
No differences were found for allelic or genotypic dis-
tributions of the polymorphisms at the 5HTT, 5HT1B,
5HT2A, 5HT1A and 5HT6 genes. The STin 2 polymor-
phism was not in Hardy–Weinberg equilibrium in the
MOH group but the size of the samples and its triallelic
distribution could account for this finding. The 5HT1B
(G861C) polymorphism was in linkage disequilibrium with
the 5-HT1B (C-261T) polymorphism, indicating that both
alleles are likely part of an extended haplotype.
On the basis of our data, these genes do not seem to be
implicated in the genetic liability either to migraine or to
MOH. These results confirm our previous negative genetic
studies performed in a different set of patients in which we
did not found any association between migraine and sero-
tonin metabolism genes [16, 17]. However, to exclude
definitively a role of the studied genes in the phenotype of
MOH, a larger sample size is recommended.
Previous associations between the 5HTT (STin 2) poly-
morphism and migraine with and without aura [18, 19]
were not confirmed in our population. However, we cannot
exclude an involvement of other 5HTT gene polymor-
phisms, such as the 5-HTTLPR, in the genetic liability to
migraine or MOH as previously reported [6, 7]. However,
STin 2 was found to be in linkage disequilibrium with 5-
HTTLPR in different populations, and the two polymor-
phisms have a combined effect on the rate of 5HTT mRNA
Table 1 Demographic data of MOH patients (n = 138, 19 M/119 F,
22–81 years)
N (%)
Clinical features
Smokers 38 (27.5%)
Ex-smokers 4 (8.7%)
Familiarity for headache 107 (77.5%)
First-grade parent with headache 103 (74.6%)
Familiarity for drug/alcohol abuse (tot.) 40 (32.6%)
Parents with headache and analgesic overuse 33 (23.9%)
Parents with alcohol abuse 11 (7.9%)
Parents with drug addiction (opioid) 2 (1.4%)
Parents with anxiolytic abuse 1 (0.7%)
Anxiety/depression comorbidity (tot.) 56 (40.5%)
Depression 47 (34%)
Anxiety 42 (30.4%)
Anxiety and depression co-presence 33 (23.9%)
Headache drug overused
Abuse of combination analgesics 91 (65.9%)
Combination with indomethacin and caffeine 41 (29.7%)
Combination with barbiturate 37 (26.8%)
Combination with ergotamine 8 (5.8%)
Combination with NSAIDs and caffeine 3 (2.2%)
Combination with opioid 2 (1.4%)
Triptans 49 (35.5%)
NSAIDs 40 (29%)
Acetaminophen 5 (3.6%)
Metamizole 2 (1.4%)
Overuse of one drug 68 (49.3%)
Overuse of more than one drug 66 (47.8%)
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Table 2 Genotypic and allelic
frequencies of 5-HT1B
polymorphism in controls,
migraine without aura and
without drug overuse (MO) and
medication overuse headache
(MOH)
Controls (n = 104) MO (n = 107) MOH (n = 105)
n (%) n (%) n (%)
5-HT1B (-261) genotype
GG 21 (0.20) 23 (0.22) 16 (0.15)
GT 44 (0.42) 44 (0.41) 46 (0.44)
TT 39 (0.38) 40 (0.37) 43 (0.41)
MO versus controls v2 = 0.061 (P = 0.970)
MOH versus controls v2 = 0.913 (P = 0.634)
MOH versus MO v2 = 1.397 (P = 0.497)
5-HT1B alleles
G 81 (0.43) 81 (0.42) 119 (0.62)
T 105 (0.57) 111 (0.58) 73 (0.38)
MO versus controls v2 = 0.02 (P = 0.883)
MOH versus controls v2 = 0.77 (P = 0.379)
MOH versus MO v2 = 1.07 (P = 0.302)
Controls (n = 103) MO (n = 110) MOH (n = 110)
n (%) n (%) n (%)
5-HT1B (861) genotype
GG 50 (0.48) 57 (0.52) 62 (0.56)
GC 48 (0.47) 46 (0.42) 44 (0.40)
CC 5 (0.05) 7 (0.06) 4 (0.04)
MO versus controls v2 = 0.606 (P = 0.739)
MOH versus controls v2 = 1.343 (P = 0.511)
MOH versus MO v2 = 1.083 (P= 0.582)
5-HT1B alleles
G 124 (0.69) 105 (0.68) 114 (0.66)
C 56 (0.31) 49 (0.32) 58 (0.34)
MO versus controls v2 = 0.04 (P = 0.839)
MOH versus controls v2 = 1.13 (P = 0.288)
MOH versus MO v2 = 0.76 (P = 0.382)
Table 3 Genotypic and allelic
frequencies of 5-HT2A
polymorphism in controls,
migraine without aura and
without drug overuse (MO) and
medication overuse headache
(MOH)
Controls (n = 100) MO (n = 98) MOH (n = 101)
n (%) n (%) n (%)
5-HT2A (102) genotype
CC 25 (0.25) 18 (0.18) 23 (0.23)
CT 50 (0.50) 53 (0.54) 58 (0.57)
TT 25 (0.25) 27 (0.28) 20 (0.20)
MO versus controls v2 = 1.289 (P = 0.525)
MOH versus controls v2 = 1.228 (P = 0.541)
MOH versus MO v2 = 1.838 (P = 0.399)
5-HT2A alleles
C 100 (0.50) 89 (0.45) 104 (0.52)
T 100 (0.50) 109 (0.55) 98 (0.48)
MO versus controls v2 = 0.83 (P = 0.361)
MOH versus controls v2 = 0.09 (P = 0.766)
MOH versus MO v2 = 1.47 (P = 0.226)
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transcription [20]. We chose to analyse the STin 2 poly-
morphism because it seems to influence the gene tran-
scription in an allele-dependent manner and may thus
modify neuronal transmission.
In conclusion, our study does not provide evidence that
polymorphisms at the 5HTT, 5-HT1A, 5HT1B, 5HT2A and
5HT6 genes play a role in the genetic predisposition to
MOH. However, we believe that our findings need confir-
mation in other genetically diverse populations. Genetic
association studies are indeed susceptible to false positives
due to genetic population diversity, population structure
and to multiple tests performed. In fact, although many
claims of associations have been published, the statistical
support tended to be weak. For that reason we chose a
conservative statistic. Another possible interpretation of
our negative results could be that they showed a tendency
to an association between the 5HT1A and 5HT6 genes and
MOH. In particular, our data could indicate a tendency
towards a protective effect of the G allele of the 5HT1A
gene versus addiction in migraine patients, and an
Table 4 Genotypic and allelic
frequencies of VNRT-2
polymorphism in controls,
migraine without aura and
without drug overuse (MO) and
medication overuse headache
(MOH)
Controls (n = 104) MO (n = 86) MOH (n = 101)
n (%) n (%) n (%)
VNRT-2 polymorphism: STin 2.8-2.9-2.12 genotype
8/12 3 (0.03) 1 (0.01) 3 (0.03)
9/9 21 (0.20) 17 (0.20) 23 (0.23)
9/12 38 (0.37) 42 (0.49) 32 (0.32)
12/12 41 (0.39) 26 (0.30) 42 (0.42)
8/9 1 (0.01) 0 (0.00) 1 (0.01)
MO versus controls v2 = 4.734 (P = 0.316)
MOH versus controls v2 = 0.574 (P = 0.966)
MOH versus MO v2 = 7.287 (P = 0.121)
VNRT-2 polymorphism: STin 2.8-2.9-2.12 alleles
8 4 (0.02) 1 (0.006) 4 (0.019)
9 81 (0.39) 79 (0.44) 81 (0.39)
12 123 (0.60) 95 (0.55) 123 (0.60)
MO versus controls v2 = 2.28 (P = 0.320)
MOH versus controls v2 = 0.01 (P = 0.998)
MOH versus MO v2 = 2.27 (P = 0.321)
Table 5 Genotypic and allelic frequencies of 5-HT1A polymorphism
in controls, migraine without aura and without drug overuse (MO)
and medication overuse headache (MOH)
Controls
(n = 94)
MO
(n = 96)
MOH
(n = 99)
5-HT1A (82) genotype
AA 90 (0.96) 88 (0.92) 97 (0.98)
AG 4 (0.04) 8 (0.08) 2 (0.002)
MO versus controls v2 = 1.361 (P = 0.243)
MOH versus controls v2 = 0.812 (P = 0.367)
MOH versus MO v2 = 4.247 (P = 0.039)*
5-HT1A alleles
A 184 (0.98) 184 (0.84) 196 (0.99)
G 4 (0.02) 8 (0.04) 2 (0.001)
MO versus controls v2 = 1.29 (P = 0.256)
MOH versus controls v2 = 0.79 (P = 0.376)
MOH versus MO v2 = 3.88 (P = 0.049)*
* Significant at P B 0.05
Table 6 Genotypic and allelic frequencies of 5-HT6 polymorphism
in controls, migraine without aura and without drug overuse (MO)
and medication overuse headache (MOH)
Controls
(n = 100)
MO
(n = 84)
MOH
(n = 99)
5-HT6 (267) genotype
TT 74 (0.74) 55 (0.65) 61 (0.62)
TC 24 (0.24) 26 (0.31) 32 (0.32)
CC 2 (0.02) 3 (0.04) 6 (0.06)
MO versus controls v2 = 1.697 (P = 0.428)
MOH versus controls v2 = 4.489 (P = 0.106)
MOH versus MO v2 = 0.721 (P = 0.697)
5-HT6 alleles
T 172 (0.86) 138 (0.84) 154 (0.77)
C 28 (0.14) 26 (0.16) 44 (0.23)
MO versus controls v2 = 1.70 (P = 0.192)
MOH versus controls v2 = 4.53 (P = 0.033)*
MOH versus MO v2 = 0.56 (P = 0.456)
* Significant at P B 0.05
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overrepresentation of allele C compared of allele T of the
5HT6 gene in MOH group. However, the statistical sig-
nificance disappeared after correction for multiple com-
parisons. If such associations were nonetheless true, our
results could be useful for future meta-analyses that could
overcome the problem of a low statistical power. Finally,
we belive that the putative pathogenetic and therapeutic
relevance of the serotoninergic system in MOH deserves
confirmation in other studies on other genes involved in the
serotonin metabolism.
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